PMID- 32664168
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 28
DP  - 2020 Jul 10
TI  - Responses of metastatic primary fallopian tube carcinoma to pembrolizumab and 
      nab-paclitaxel: A case report.
PG  - e21203
LID - 10.1097/MD.0000000000021203 [doi]
LID - e21203
AB  - RATIONALE: Primary fallopian tube carcinoma (PFTC) is an extremely rare but 
      invasive malignancy with a dismal prognosis. Very few data exist on the salvage 
      treatment for patients with PFTC. Here we report a case showing an impressive 
      response to immunotherapy combined with chemotherapy, which have never been 
      reported before on patients with metastatic PFTC. PATIENT CONCERNS: A 42-year-old 
      woman, who was diagnosed with PFTC in 2010, had been failed of multiple systemic 
      therapies and antiangiogenic therapy because of the disease recurrence and 
      progression. DIAGNOSIS: Metastatic primary fallopian tube carcinoma. 
      INTERVENTIONS: The patient underwent surgery in May 2010 and had multi-line 
      chemotherapies plus an anti-vascular endothelial growth factor (anti-VEGF) 
      monoclonal antibody for about 9 years. Due to treatment failure the patient 
      accepted the immunotherapy with the checkpoint inhibitor, pembrolizumab, combined 
      with nab-paclitaxel from December 2018 to April 2019. OUTCOMES: The patient 
      showed a complete response after 6 cycles treatment. Thus far, the patient is 
      taking pembrolizumab as maintenance and remains in good health. LESSONS: 
      Pembrolizumab combined with chemotherapy for treatment of PFTC may provide a 
      positive antitumor effect in multiple metastatic lesions, but more clinical 
      evidence is needed to confirm the efficacy and safety.
FAU - Jiang, Jian
AU  - Jiang J
AD  - Department of Oncology, The Affiliated Zhangjiagang Hospital of Soochow 
      University, Suzhou, China.
FAU - Chen, Zhi-Peng
AU  - Chen ZP
FAU - Zhu, Hui-Ping
AU  - Zhu HP
FAU - Zhang, Yong-Qin
AU  - Zhang YQ
FAU - Qian, Xiao-Lan
AU  - Qian XL
FAU - Zhang, Min
AU  - Zhang M
FAU - Ni, Chen
AU  - Ni C
FAU - Zuo, Yun
AU  - Zuo Y
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (130-nm albumin-bound paclitaxel)
RN  - 0 (Albumins)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - DPT0O3T46P (pembrolizumab)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Albumins/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma/*drug therapy
MH  - Fallopian Tube Neoplasms/*drug therapy
MH  - Female
MH  - Humans
MH  - Paclitaxel/*therapeutic use
PMC - PMC7360280
COIS- The authors declare that they have no competing interests. The authors have no 
      conflicts of interest to disclose.
EDAT- 2020/07/16 06:00
MHDA- 2020/07/28 06:00
PMCR- 2020/07/10
CRDT- 2020/07/16 06:00
PHST- 2020/07/16 06:00 [entrez]
PHST- 2020/07/16 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
PHST- 2020/07/10 00:00 [pmc-release]
AID - 00005792-202007100-00118 [pii]
AID - MD-D-19-08739 [pii]
AID - 10.1097/MD.0000000000021203 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 10;99(28):e21203. doi: 
      10.1097/MD.0000000000021203.